Urinary tract infection of mice to model human disease: Practicalities, implications and limitations

Critical Reviews in Microbiology

Volumn 42, Issue 5, 2016, Pages 780-799

  Carey, Alison J ^a   Tan, Chee K ^a   Ipe, Deepak S ^a   Sullivan, Matthew J ^a   Cripps, Allan W ^a   Schembri, Mark A ^b   Ulett, Glen C ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Animal models; bacterial pathogenesis; Escherichia coli; innate immunity; urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ESCHERICHIA COLI VACCINE; LIPOPOLYSACCHARIDE; SIDEROPHORE; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5;

ANIMAL MODEL; ANTIBIOTIC THERAPY; BIOFILM; CHIMERA; CYTOKINE RESPONSE; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INOCULATION; KLEBSIELLA; MICROBIAL COMMUNITY; MORGANELLA MORGANII; MOUSE; MOUSE STRAIN; MURINE MODEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROVIDENCIA STUARTII; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS AGALACTIAE; TRANSCRIPTOMICS; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; VACCINATION; ANIMAL; BACTERIAL INFECTION; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM; DISEASE MODEL; GENETICS; MICROBIOLOGY; PATHOLOGY;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; DISEASE MODELS, ANIMAL; HUMANS; MICE; URINARY TRACT INFECTIONS;

EID: 84979555295     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2015.1028885     Document Type: Review

References (274)

1. W.W.Agace. (1996). The role of the epithelial cell in Escherichia coli induced neutrophil migration into the urinary tract. Eur Respir J 9:1713–28
2. W.W.Agace, S.R.Hedges, M.Ceska, C.Svanborg. (1993). Interleukin-8 and the neutrophil response to mucosal gram-negative infection. J Clin Invest 92:780–5
3. I.Akil, F.Ozkinay, H.Onay,. (2012). Assessment of toll-like receptor-4 gene polymorphism on pyelonephritis and renal scar. Int J Immunogenet 39:303–7
4. P.Alamuri, K.A.Eaton, S.D.Himpsl,. (2009). Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Infect Immun 77:632–41
5. L.P.Allsopp, C.Beloin, G.C.Ulett,. (2012). Molecular characterization of UpaB and UpaC two new autotransporter proteins of uropathogenic Escherichia coli CFT073. Infect Immun 80:321–32
6. L.P.Allsopp, M.Totsika, J.J.Tree,. (2010). UpaH is a newly identified autotransporter protein that contributes to biofilm formation and bladder colonization by uropathogenic Escherichia coli CFT073. Infect Immun 78:1659–69
7. C.J.Alteri, E.C.Hagan, K.E.Sivick,. (2009a). Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog 5:e1000586
8. C.J.Alteri, H.L.Mobley. (2007). Quantitative profile of the uropathogenic Escherichia coli outer membrane proteome during growth in human urine. Infect Immun 75:2679–88
9. C.J.Alteri, S.N.Smith, H.L.Mobley. (2009b). Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle. PLoS Pathog 5:e1000448
10. E.Andersen-Nissen, T.R.Hawn, K.D.Smith,. (2007). Cutting edge: Tlr5−/− mice are more susceptible to Escherichia coli urinary tract infection. J Immunol 178:4717–20
11. G.G.Anderson, C.C.Goller, S.Justice,. (2010). Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. Infect Immun 78:963–75
12. G.G.Anderson, J.J.Palermo, J.D.Schilling,. (2003). Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105–7
13. C.E.Armbruster, S.N.Smith, A.Yep, H.L.Mobley. (2014). Increased incidence of urolithiasis and bacteremia during Proteus mirabilis and Providencia stuartii coinfection due to synergistic induction of urease activity. J Infect Dis 209:1524–32
14. L.Artifoni, S.Negrisolo, G.Montini,. (2007). Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J Urol 177:1102–6
15. M.R.Asadi Karam, M.Oloomi, M.Mahdavi,. (2013). Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 31:1210–16
16. W.Baier, E.A.Sedelmeier, W.G.Bessler. (1997). Studies on the immunogenicity of an Escherichia coli extract after oral application in mice. Arzneim-Forsch 47:980–5
17. A.Bala, S.Chhibber, K.Harjai. (2014). Pseudomonas quinolone signalling system: a component of quorum sensing cascade is a crucial player in the acute urinary tract infection caused by Pseudomonas aeruginosa. Int J Med Microbiol 304:1199--208
18. N.L.Barbieri, B.Nicholson, A.Hussein,. (2014). FNR regulates expression of important virulence factors contributing to pathogenicity of uropathogenic Escherichia coli. Infect Immun 82:5086–98
19. B.J.Barnett, D.S.Stephens. (1997). Urinary tract infection: an overview. Am J Med Sci 314:245–9
20. J.M.Bates, H.M.Raffi, K.Prasadan,. (2004). Tamm–Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791–7
21. W.G.Bessler, K.Puce, U.Vor Dem Esche,. (2009). Immunomodulating effects of OM-89, a bacterial extract from Escherichia coli, in murine and human leukocytes. Arzneim-Forsch 59:571–7
22. W.G.Bessler, U.Vor Dem Esche, A.Zgaga-Griesz, R.Ataullakhanov. (2010). Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo. Arzneim-Forsch 60:324–9
23. P.Bielecki, U.Muthukumarasamy, D.Eckweiler,. (2014). In vivo mRNA profiling of uropathogenic Escherichia coli from diverse phylogroups reveals common and group-specific gene expression profiles. MBio 5:e01075–14
24. B.K.Billips, S.G.Forrestal, M.T.Rycyk,. (2007). Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli. Infect Immun 75:5353–60
25. M.G.Blango, M.A.Mulvey. (2010). Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54:1855–63
26. N.J.Bokil, M.Totsika, A.J.Carey,. (2011). Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages. Immunobiology 216:1164–71
27. M.Bolton, D.J.HorvathJr, B.Li,. (2012). Intrauterine growth restriction is a direct consequence of localized maternal uropathogenic Escherichia coli cystitis. PLoS One 7:e33897
28. A.Bosch, V.J.Benedi, R.Pares, J.Jofre. (1988). Enhancement of the humoral immune response and resistance to bacterial infection in mice by the oral administration of a bacterial immunomodulator (OM-89). Immunopharm Immunotoxicol 10:333–43
29. J.M.Bower, D.S.Eto, M.A.Mulvey. (2005). Covert operations of uropathogenic Escherichia coli within the urinary tract. Traffic 6:18–31
30. P.D.Brown. (1999). Antibiotic selection for urinary tract infection: new microbiologic considerations. Cur Infect Dis Rep 1:384–8
31. A.R.Brumbaugh, H.L.Mobley. (2012). Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11:663–76
32. A.R.Brumbaugh, S.N.Smith, H.L.Mobley. (2013). Immunization with the yersiniabactin receptor, FyuA protects against pyelonephritis in a murine model of urinary tract infection. Infect Immun 81:3309–16
33. J.V.Candela, E.Park, J.M.Gerspach,. (1998). Evaluation of urinary IL-1alpha and IL-1beta in gravid females and patients with bacterial cystitis and microscopic hematuria. Urol Res 26:175–80
34. C.Y.Chan, A.L.St John, S.N.Abraham. (2013). Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38:349–59
35. C.Chassin, J.M.Goujon, S.Darche,. (2006). Renal collecting duct epithelial cells react to pyelonephritis-associated Escherichia coli by activating distinct TLR4-dependent and -independent inflammatory pathways. J Immunol 177:4773–84
36. C.Chassin, W.Hornefm, M.Bens,. (2007). Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J Exp Med 204:2837–52
37. S.L.Chen, C.S.Hung, J.S.Pinkner,. (2009). Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci USA 106:22439–44
38. C.Chenoweth, S.Saint. (2013). Preventing catheter-associated urinary tract infections in the intensive care unit. Crit Care Clin 29:19–32
39. M.Chromek, Z.Slamova, P.Bergman,. (2006). The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 12:636–41
40. F.C.Chuang, H.C.Kuo. (2013). Increased urothelial cell apoptosis and chronic inflammation are associated with recurrent urinary tract infection in women. PLoS One 8:e63760
41. C.Cirl, A.Wieser, M.Yadav,. (2008). Subversion of toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat Med 14:399–406
42. S.J.Cole, A.R.Records, M.W.Orr,. (2014). Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms. Infect Immun 82:2048–58
43. I.Connell, W.Agace, P.Klemm,. (1996). Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci USA 93:9827–32
44. C.K.Cusumano, J.S.Pinkner, Z.Han,. (2011). Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 3:109ra115
45. E.S.Danka, D.A.Hunstad. (2015). Cathelicidin augments epithelial receptivity and pathogenesis in experimental Escherichia coli cystitis. J Infect Dis 211:1164--73
46. P.H.Davis, S.L.StanleyJr. (2003). Breaking the species barrier: use of SCID mouse–human chimeras for the study of human infectious diseases. Cell Microbiol 5:849–60
47. P.De Man, C.Van Kooten, L.Aarden,. (1989). Interleukin-6 induced at mucosal surfaces by gram-negative bacterial infection. Infect Immun 57:3383–8
48. F.Deknuydt, E.Scotet, M.Bonneville. (2009). Modulation of inflammation through IL-17 production by gammadelta T cells: mandatory in the mouse, dispensable in humans? Immunol Lett 127:8–12
49. B.K.Dhakal, M.A.Mulvey. (2012). The UPEC pore-forming toxin alpha-hemolysin triggers proteolysis of host proteins to disrupt cell adhesion, inflammatory, and survival pathways. Cell Host Microbe 11:58–69
50. B.L.Duell, A.J.Carey, S.J.Dando,. (2013). Human bladder uroepithelial cells synergize with monocytes to promote IL-10 synthesis and other cytokine responses to uropathogenic Escherichia coli. PLoS One 8:e78013
51. B.L.Duell, A.J.Carey, C.K.Tan,. (2012a). Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol 188:781–92
52. B.L.Duell, C.K.Tan, A.J.Carey,. (2012b). Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol 64:295–313
53. H.Fischer, N.Lutay, B.Ragnarsdottir,. (2010). Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection. PLoS Pathog 6:e1001109
54. H.Fischer, M.Yamamoto, S.Akira,. (2006). Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur J Immunol 36:267–77
55. A.L.Flores-Mireles, J.S.Pinkner, M.G.Caparon, S.J.Hultgren. (2014). EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci Transl Med 6:254ra127
56. B.Foxman. (1990). Recurring urinary tract infection: incidence and risk factors. Am J Public Health 80:331–3
57. B.Foxman. (2002). Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113:5S–13S
58. B.Foxman. (2003). Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Disease-a-Month 49:53–70
59. A.V.Franco. (2005). Recurrent urinary tract infections. Best Pract Res Clin Obstet Gynaecol 19:861–73
60. D.N.Frank, S.S.Wilson, A.L.St Amand, N.R.Pace. (2009). Culture-independent microbiological analysis of foley urinary catheter biofilms. PLoS One 4:e7811
61. B.Frendeus, G.Godaly, L.Hang,. (2000). Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart. J Exp Med 192:881–90
62. D.Furtado. (1976). Experimental group B streptococcal infections in mice: hematogenous virulence and mucosal colonization. Infect Immun 13:1315–20
63. D.L.Gally, J.Leathart, I.C.Blomfield. (1996). Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriae in Escherichia coli K-12. Mol Microbiol 21:725–38
64. E.C.Garcia, A.R.Brumbaugh, H.L.Mobley. (2011). Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect Immun 79:1225–35
65. T.A.Garcia, C.L.Ventura, M.A.Smith,. (2013). Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder. Infect Immun 81:99–109
66. C.K.Garofalo, T.M.Hooton, S.M.Martin,. (2007). Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect Immun 75:52–60
67. G.Godaly, L.Hang, B.Frendeus, C.Svanborg. (2000). Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice. J Immunol 165:5287–94
68. G.Godaly, G.Otto, M.D.Burdick,. (2007). Fimbrial lectins influence the chemokine repertoire in the urinary tract mucosa. Kidney Int 71:778–86
69. C.C.Goller, M.Arshad, J.W.Noah,. (2014). Lifting the mask: identification of new small molecule inhibitors of uropathogenic Escherichia coli group 2 capsule biogenesis. PLoS One 9:e96054
70. P.S.Guiton, C.K.Cusumano, K.A.Kline,. (2012). Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob Agents Chemother 56:4738–45
71. P.S.Guiton, C.S.Hung, L.E.Hancock,. (2010). Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections. Infect Immun 78:4166–75
72. M.Hadjifrangiskou, A.P.Gu, J.S.Pinkner,. (2012). Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors. J Bacteriol 194:6195–205
73. E.C.Hagan, A.L.Lloyd, D.A.Rasko,. (2010). Escherichia coli global gene expression in urine from women with urinary tract infection. PLoS Pathog 6:e1001187
74. E.C.Hagan, H.L.Mobley. (2009). Haem acquisition is facilitated by a novel receptor Hma and required by uropathogenic Escherichia coli for kidney infection. Mol Microbiol 71:79–91
75. L.Hagberg, I.Engberg, R.Freter,. (1983). Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect Immun 40:273–83
76. L.Hagberg, R.Hull, S.Hull,. (1984). Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun 46:839–44
77. L.Hagberg, U.Jodal, T.K.Korhonen. (1981). Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections. Infect Immun 31:564–70
78. Z.Han, J.S.Pinkner, B.Ford,. (2010). Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53:4779–92
79. L.Hang, B.Frendeus, G.Godaly, C.Svanborg. (2000). Interleukin-8 receptor knockout mice have subepithelial neutrophil entrapment and renal scarring following acute pyelonephritis. J Infect Dis 182:1738–48
80. T.J.Hannan, I.U.Mysorekar, C.S.Hung,. (2010). Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6:e1001042
81. T.J.Hannan, P.L.Roberts, T.E.Riehl,. (2014). Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBioMedicine 1:46--57
82. T.J.Hannan, M.Totsika, K.J.Mansfield,. (2012). Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 36:616–48
83. T.R.Hawn, D.Scholes, S.S.Li,. (2009). Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS ONE 4:e5990
84. A.D.Hay, T.Fahey. (2002). Clinical diagnosis of urinary tract infection. J Am Med Assoc 288:1229; author reply 1230–1
85. E.F.Healy, C.A.Walsh, A.M.Cotter, S.R.Walsh. (2012). Suprapubic compared with transurethral bladder catheterization for gynecologic surgery: a systematic review and meta-analysis. Obstet Gynecol 120:678–87
86. S.Hedges, W.Agace, M.Svensson,. (1994). Uroepithelial cells are part of a mucosal cytokine network. Infect Immun 62:2315–21
87. S.Hedges, M.Svensson, C.Svanborg. (1992). Interleukin-6 response of epithelial cell lines to bacterial stimulation in vitro. Infect Immun 60:1295–301
88. J.G.Hernandez, F.Sunden, J.Connolly,. (2011). Genetic control of the variable innate immune response to asymptomatic bacteriuria. PLoS One 6:e28289
89. K.P.High, S.F.Bradley, S.Gravenstein,. (2009). Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 48:149–71
90. D.W.Hilbert, T.E.Paulish-Miller, C.K.Tan,. (2012). Clinical Escherichia coli isolates utilize alpha-hemolysin to inhibit in vitro epithelial cytokine production. Microbes Infect 14:628–38
91. K.Hoelzer, R.Pouillot, S.Dennis. (2012). Animal models of listeriosis: a comparative review of the current state of the art and lessons learned. Vet Res 43:18
92. A.I.Hoepelman, R.Meiland, S.E.Geerlings. (2003). Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 22:35–43
93. V.Hola, T.Peroutkova, F.Ruzicka. (2012). Virulence factors in Proteus bacteria from biofilm communities of catheter-associated urinary tract infections. FEMS Immunol Med Microbiol 65:343–9
94. T.M.Hooton, D.Scholes, J.P.Hughes,. (1996). A prospective study of risk factors for symptomatic urinary tract infection in young women. New Engl J Med 335:468–74
95. W.J.Hopkins, A.Gendron-Fitzpatrick, E.Balish, D.T.Uehling. (1998). Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect Immun 66:2798–802
96. W.J.Hopkins, J.A.Hall, B.P.Conway, D.T.Uehling. (1995). Induction of urinary tract infection by intraurethral inoculation with Escherichia coli: refining the murine model. J Infect Dis 171:462–5
97. W.J.Hopkins, L.J.James, E.Balish, D.T.Uehling. (1993). Congenital immunodeficiencies in mice increase susceptibility to urinary tract infection. J Urol 149:922–5
98. M.Huber, K.Krauter, G.Winkelmann,. (2000). Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int J Immunopharmacol 22:1103–11
99. F.M.HughesJr, N.P.Vivar, J.G.Kennis,. (2014). Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation. Am J Physiol Renal Physiol 306: F299–308
100. R.Hull, D.Rudy, W.Donovan,. (2000). Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. J Urol 163:872–7
101. C.S.Hung, K.W.Dodson, S.J.Hultgren. (2009). A murine model of urinary tract infection. Nat Protocols 4:1230–43
102. D.A.Hunstad, S.S.Justice. (2010). Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol 64:203–21
103. H.Hvidberg, C.Struve, K.A.Krogfelt,. (2000). Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother 44:156–63
104. T.Ichinohe, I.K.Pang, Y.Kumamoto,. (2011). Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 108:5354–9
105. M.A.Ingersoll, K.A.Kline, H.V.Nielsen, S.J.Hultgren. (2008). G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 10:2568–78
106. D.S.Ipe, L.Sundac, W.H.BenjaminJr,. (2013). Asymptomatic bacteriuria: prevalence rates of causal microorganisms, etiology of infection in different patient populations, and recent advances in molecular detection. FEMS Microbiol Lett 346:1–10
107. T.Iwahi, Y.Abe, K.Tsuchiya. (1982). Virulence of Escherichia coli in ascending urinary-tract infection in mice. J Med Microbiol 15:303–16
108. S.M.Jacobsen, D.J.Stickler, H.L.Mobley, M.E.Shirtliff. (2008). Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 21:26–59
109. S.Jaillon, F.Moalli, B.Ragnarsdottir,. (2014). The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity 40:621–32
110. C.Janssen, J.Lo, W.Jager,. (2014). A high throughput, minimally invasive, ultrasound guided model for the study of catheter associated urinary tract infections and device encrustation in mice. J Urol 192:1856–63
111. T.E.Johansen, H.Botto, M.Cek,. (2011). Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents 38:64–70
112. J.R.Johnson. (1998). Reflux in the mouse model of urinary tract infection. Infect Immun 66:6063–4
113. J.R.Johnson, J.J.Brown. (1996). Defining inoculation conditions for the mouse model of ascending urinary tract infection that avoid immediate vesicoureteral reflux yet produce renal and bladder infection. J Infect Dis 173:746–9
114. J.R.Johnson, C.Clabots, H.Rosen. (2006). Effect of inactivation of the global oxidative stress regulator oxyR on the colonization ability of Escherichia coli O1:K1:H7 in a mouse model of ascending urinary tract infection. Infect Immun 74:461–8
115. J.R.Johnson, P.Delavari, M.Azar. (1999). Activities of a nitrofurazone-containing urinary catheter and a silver hydrogel catheter against multidrug-resistant bacteria characteristic of catheter-associated urinary tract infection. Antimicrob Agents Chemother 43:2990–5
116. J.R.Johnson, J.C.Manivel. (1991). Vesicoureteral reflux induces renal trauma in a mouse model of ascending, unobstructed pyelonephritis. J Urol 145:1306–11
117. D.E.Johnson, C.V.Lockatell, M.Hall-Craigs,. (1987). Uropathogenicity in rats and mice of Providencia stuartii from long-term catheterized patients. J Urol 138:632–5
118. D.E.Johnson, C.V.Lockatell, R.G.Russell,. (1998). Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice. Infect Immun 66:3059–65
119. D.E.Johnson, R.G.Russell, C.V.Lockatell,. (1993a). Urethral obstruction of 6 hours or less causes bacteriuria, bacteremia, and pyelonephritis in mice challenged with “nonuropathogenic” Escherichia coli. Infect Immun 61:3422–8
120. D.E.Johnson, R.G.Russell, C.V.Lockatell,. (1993b). Contribution of Proteus mirabilis urease to persistence, urolithiasis, and acute pyelonephritis in a mouse model of ascending urinary tract infection. Infect Immun 61:2748–54
121. J.Jones-Carson, E.Balish, D.T.Uehling. (1999). Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. J Urol 161:338–41
122. Y.Kai-Larsen, P.Luthje, M.Chromek,. (2010). Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog 6:e1001010
123. G.M.Kalmanson, H.J.Harwick, M.Turck, L.B.Guze. (1975). Urinary-tract infection: localisation and virulence of Escherichia coli. Lancet 1:134–6
124. J.Kaufmann, G.A.Modest. (2002). Clinical diagnosis of urinary tract infection. J Am Med Assoc 288:1229–30; author reply 1230–1
125. A.K.Kaul, S.Khan, M.G.Martens,. (1999). Experimental gestational pyelonephritis induces preterm births and low birth weights in C3H/HeJ mice. Infect Immun 67:5958–66
126. K.D.Kemp, K.V.Singh, S.R.Nallapareddy, B.E.Murray. (2007). Relative contributions of Enterococcus faecalis OG1RF sortase-encoding genes, srtA and bps (srtC), to biofilm formation and a murine model of urinary tract infection. Infect Immun 75:5399–404
127. K.A.Kline, D.J.Schwartz, N.M.Gilbert,. (2012). Immune modulation by group B streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli. Infect Immun 80:4186–94
128. K.A.Kline, D.J.Schwartz, N.M.Gilbert, A.L.Lewis. (2014). Impact of host age and parity on susceptibility to severe urinary tract infection in a murine model. PLoS One 9:e97798
129. K.A.Kline, D.J.Schwartz, W.G.Lewis,. (2011). Immune activation and suppression by group B streptococcus in a murine model of urinary tract infection. Infect Immun 79:3588–95
130. Y.C.Ko, N.Mukaida, S.Ishiyama,. (1993). Elevated interleukin-8 levels in the urine of patients with urinary tract infections. Infect Immun 61:1307–14
131. M.Kostakioti, M.Hadjifrangiskou, C.K.Cusumano,. (2012). Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection. Infect Immun 80:2826–34
132. B.Koves, E.Salvador, J.Gronberg-Hernandez,. (2014). Rare emergence of symptoms during long-term asymptomatic Escherichia coli 83972 carriage without an altered virulence factor repertoire. J Urol 191:519–28
133. C.M.Kunin. (1994). Urinary tract infections in females. Clin Infect Dis 18:1–10; quiz 11–12
134. M.C.Lane, C.J.Alteri, S.N.Smith, H.L.Mobley. (2007). Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natil Acad Sci USA 104:16669–74
135. M.C.Lane, V.Lockatell, G.Monterosso,. (2005). Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun 73:7644–56
136. S.Langermann, S.Palaszynski, M.Barnhart,. (1997). Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276:607–11
137. J.B.L.Lee, G.H.Neild. (2007). Urinary tract infection. Medicine 35:423–8
138. A.Lefort, F.Chau, R.Lepeule,. (2014). Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum beta-lactamase. Int J Antimicrob Agents 43:366–9
139. C.R.Li, Y.Li, G.Q.Li,. (2010). In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother 65:2411–15
140. X.Li, H.Zhao, C.V.Lockatell,. (2002). Visualization of Proteus mirabilis within the matrix of urease-induced bladder stones during experimental urinary tract infection. Infect Immun 70:389–94
141. D.Louz, H.E.Bergmans, B.P.Loos, R.C.Hoeben. (2013). Animal models in virus research: their utility and limitations. Crit Rev Microbiol 39:325–61
142. D.G.Maki, P.A.Tambyah. (2001). Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 7:342–7
143. P.Mastroeni, M.Sheppard. (2004). Salmonella infections in the mouse model: host resistance factors and in vivo dynamics of bacterial spread and distribution in the tissues. Microbes Infect 6:398–405
144. M.Mcbean, S.Rajamani. (2001). Increasing rates of hospitalization due to septicemia in the US elderly population, 1986–1997. J Infect Dis 183:596–603
145. J.Meddings, M.A.Rogers, M.Macy, S.Saint. (2010). Systematic review and meta-analysis: reminder systems to reduce catheter-associated urinary tract infections and urinary catheter use in hospitalized patients. Clin Infect Dis 51:550–60
146. H.L.Mobley, D.M.Green, A.L.Trifillis,. (1990). Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun 58:1281–9
147. H.L.Mobley, K.G.Jarvis, J.P.Elwood,. (1993). Isogenic P-fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of alpha Gal(1–4) beta Gal binding in virulence of a wild-type strain. Mol Microbiol 10:143–55
148. D.G.Moriel, M.A.Schembri. (2013). Vaccination approaches for the prevention of urinary tract infection. Curr Pharm Biotechnol 14:967–74
149. M.D.Morin, W.J.Hopkins. (1998). Treatment of mice with staphylococcal enterotoxin B enhances resolution of an induced Escherichia coli urinary tract infection and stimulates production of proinflammatory cytokines. Infect Immun 66:2466–70
150. M.A.Mulvey. (2002). Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol 4:257–71
151. M.A.Mulvey, J.D.Schilling, S.J.Hultgren. (2001). Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 69:4572–9
152. C.N.Murphy, M.S.Mortensen, K.A.Krogfelt, S.Clegg. (2013). Role of Klebsiella pneumoniae type 1 and type 3 fimbriae in colonizing silicone tubes implanted into the bladders of mice as a model of catheter-associated urinary tract infections. Infect Immun 81:3009–17
153. E.Mylonakis, A.Casadevall, F.M.Ausubel. (2007). Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog 3:e101
154. I.U.Mysorekar, M.A.Mulvey, S.J.Hultgren, J.I.Gordon. (2002). Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J Biol Chem 277:7412–19
155. V.Natarajan. (2008). Urinary tract infection. Surgery (Oxford) 26:193–6
156. G.H.Neild. (2003). Urinary tract infection. Medicine (Abingdon) 31:85–90
157. K.J.Ness-Schwickerath, C.T.Morita. (2011). Regulation and function of IL-17A- and IL-22-producing gammadelta T cells. Cell Mol Life Sci 68:2371–90
158. B.Nesta, G.Spraggon, C.Alteri,. (2012). FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3:e00010–12
159. A.M.Nicholson, A.A.Glynn. (1975). Investigation of the effect of K antigen in Escherichia coli urinary tract infections by use of a mouse model. Br J Exp Pathol 56:549–53
160. L.E.Nicolle. (2008). Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am 35:1–12, v
161. L.E.Nicolle. (2014). Catheter associated urinary tract infections. Antimicrob Resist Infect Control 3:23--30
162. H.V.Nielsen, P.S.Guiton, K.A.Kline,. (2012). The metal ion-dependent adhesion site motif of the Enterococcus faecalis EbpA pilin mediates pilus function in catheter-associated urinary tract infection. MBio 3:e00177–12
163. K.L.Nielsen, P.Dynesen, P.Larsen,. (2014). Role of urinary cathelicidin LL-37 and human beta-defensin 1 in uncomplicated Escherichia coli urinary tract infections. Infect Immun 82:1572–8
164. G.R.Nielubowicz, H.L.Mobley. (2010). Host–pathogen interactions in urinary tract infection. Nat Rev Urol 7:430–41
165. P.O'Hanley, D.Lark, S.Falkow, G.Schoolnik. (1985). Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal–Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis. J Clin Invest 75:347–60
166. J.Z.Oh, R.Ravindran, B.Chassaing,. (2014). TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 41:478–92
167. Olson PD, Hunstad DA. (2014). A new model of urinary tract infection reveals male susceptibility to chronic cystitis and severe pyelonephritis. American Society for Microbiology, 114th General Meeting. Boston, USA
168. C.L.Ong, G.C.Ulett, A.N.Mabbett,. (2008). Identification of type 3 fimbriae in uropathogenic Escherichia coli reveals a role in biofilm formation. J Bacteriol 190:1054–63
169. I.K.Pang, A.Iwasaki. (2012). Control of antiviral immunity by pattern recognition and the microbiome. Immunol Rev 245:209–26
170. M.M.Pearson, A.Yep, S.N.Smith, H.L.Mobley. (2011). Transcriptome of Proteus mirabilis in the murine urinary tract: virulence and nitrogen assimilation gene expression. Infect Immun 79:2619–31
171. B.Pecha, D.Low, P.O'Hanley. (1989). Gal–Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal–Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains. J Clin Invest 83:2102–8
172. R.Pellegrino, U.Galvalisi, P.Scavone,. (2003). Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. FEMS Immunol Med Microbiol 36:103–10
173. M.J.Press, J.P.Metlay. (2013). Catheter-associated urinary tract infection: does changing the definition change quality? Infect Control Hosp Epidemiol 34:313–15
174. H.S.Raffi, J.M.BatesJr, Z.Laszik, S.Kumar. (2005). Tamm–Horsfall protein acts as a general host-defense factor against bacterial cystitis. Am J Nephrol 25:570–8
175. H.S.Raffi, J.M.BatesJr, Z.Laszik, S.Kumar. (2009). Tamm–Horsfall protein protects against urinary tract infection by Proteus mirabilis. J Urol 181:2332–8
176. B.Ragnarsdottir, H.Fischer, G.Godaly,. (2008). TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 38:12–20
177. B.Ragnarsdottir, K.Jonsson, A.Urbano,. (2010). Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. PLoS One 5:e10734
178. B.Ragnarsdottir, N.Lutay, J.Gronberg-Hernandez,. (2011). Genetics of innate immunity and UTI susceptibility. Nat Rev Urol 8:449–68
179. B.Ragnarsdottir, M.Samuelsson, M.C.Gustafsson,. (2007). Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 196:475–84
180. R.Raz, Y.Gennesin, J.Wasser,. (2000). Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 30:152–6
181. C.S.Reigstad, S.J.Hultgren, J.I.Gordon. (2007). Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled. J Biol Chem 282:21259–67
182. L.Robino, P.Scavone, L.Araujo,. (2013). Detection of intracellular bacterial communities in a child with Escherichia coli recurrent urinary tract infections. Pathog Dis 68:78–81
183. L.Robino, P.Scavone, L.Araujo,. (2014). Intracellular bacteria in the pathogenesis of Escherichia coli urinary tract infection in children. Clin Infect Dis 59:e158--64
184. J.J.Roelofs, K.M.Rouschop, G.J.Teske,. (2006). The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int 70:1942–7
185. A.Ronald. (2002). The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 113:14S–19S
186. A.Ronald. (2003). The etiology of urinary tract infection: traditional and emerging pathogens. Disease-a-Month 49:71–82
187. V.Roos, P.Klemm. (2006). Global gene expression profiling of the asymptomatic bacteriuria Escherichia coli strain 83972 in the human urinary tract. Infect Immun 74:3565–75
188. V.Roos, G.C.Ulett, M.A.Schembri, P.Klemm. (2006). The asymptomatic bacteriuria Escherichia coli strain 83972 outcompetes uropathogenic E. coli strains in human urine. Infect Immun 74:615–24
189. D.A.Rosen, T.M.Hooton, W.E.Stamm,. (2007). Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 4:e329
190. D.A.Rosen, C.S.Hung, K.A.Kline, S.J.Hultgren. (2008). Streptozocin-induced diabetic mouse model of urinary tract infection. Infect Immun 76:4290–8
191. C.N.Rudick, B.K.Billips, V.I.Pavlov,. (2010). Host–pathogen interactions mediating pain of urinary tract infection. J Infect Dis 201:1240–9
192. T.Russo, J.J.Brown, S.T.Jodush, J.R.Johnson. (1996a). The O4 specific antigen moiety of lipopolysaccharide but not the K54 group 2 capsule is important for urovirulence of an extraintestinal isolate of Escherichia coli. Infect Immun 64:2343–8
193. T.A.Russo, S.T.Jodush, J.J.Brown, J.R.Johnson. (1996b). Identification of two previously unrecognized genes (guaA and argC) important for uropathogenesis. Mol Microbiol 22:217–29
194. T.A.Russo, C.D.Mcfadden, U.B.Carlino-Macdonald,. (2003). The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect Immun 71:7164–9
195. M.Sabri, S.Houle, C.M.Dozois. (2009). Roles of the extraintestinal pathogenic Escherichia coli ZnuACB and ZupT zinc transporters during urinary tract infection. Infect Immun 77:1155–64
196. M.D.Saemann, T.Weichhart, M.Zeyda,. (2005). Tamm–Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a toll-like receptor-4-dependent mechanism. J Clin Invest 115:468–75
197. S.Salvatore, S.Salvatore, E.Cattoni,. (2011). Urinary tract infections in women. Eur J Obstet Gynecol Reproduct Biol 156:131–6
198. T.C.Savidge, A.L.Morey, D.J.Ferguson,. (1995). Human intestinal development in a severe-combined immunodeficient xenograft model. Differentiation 58:361–71
199. P.Scavone, A.Umpierrez, A.Rial,. (2014). Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein. Anton van Leeuw 105:1139–48
200. M.A.Schembri, E.V.Sokurenko, P.Klemm. (2000). Functional flexibility of the FimH adhesin: insights from a random mutant library. Infect Immun 68:2638–46
201. J.D.Schilling, R.G.Lorenz, S.J.Hultgren. (2002). Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect Immun 70:7042–9
202. J.D.Schilling, S.M.Martin, C.S.Hung,. (2003). Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proc Natl Acad Sci USA 100:4203–8
203. J.D.Schilling, M.A.Mulvey, S.J.Hultgren. (2001a). Dynamic interactions between host and pathogen during acute urinary tract infections. Urology 57:56–61
204. J.D.Schilling, M.A.Mulvey, C.D.Vincent,. (2001b). Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol 166:1148–55
205. M.A.Schmidt, P.O'Hanley, D.Lark, G.K.Schoolnik. (1988). Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model. Proc Natl Acad Sci USA 85:1247–51
206. C.Schneeberger, B.M.Kazemier, S.E.Geerlings. (2014). Asymptomatic bacteriuria and urinary tract infections in special patient groups: women with diabetes mellitus and pregnant women. Curr Opin Infect Dis 27:108–14
207. D.Scholes, T.M.Hooton, P.L.E.A.E.RobertsPL, et al. E. (2000). Risk factors for recurrent urinary tract infection in young women. J Infect Dis 182:1177–82
208. D.J.Schwartz, M.S.Conover, T.J.Hannan, S.J.Hultgren. (2015). Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. PLoS Pathog 11:e1004599
209. J.Seok, H.S.Warren, A.G.Cuenca,. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507–12
210. N.Shankar, C.V.Lockatell, A.S.Baghdayan,. (2001). Role of Enterococcus faecalis surface protein Esp in the pathogenesis of ascending urinary tract infection. Infect Immun 69:4366–72
211. H.E.Sidjabat, J.J.Chin, T.Chapman,. (2009). Colonisation dynamics and virulence of two clonal groups of multidrug-resistant Escherichia coli isolated from dogs. Microbes Infect 11:100–7
212. Y.Siegman-Igra, B.Fourer, R.Orni-Wasserlaufr,. (2002). Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 34:1431–9
213. J.Sillanpaa, S.R.Nallapareddy, K.V.Singh,. (2010). Characterization of the ebp(fm) pilus-encoding operon of Enterococcus faecium and its role in biofilm formation and virulence in a murine model of urinary tract infection. Virulence 1:236–46
214. T.M.Silva, E.A.Costa, T.A.Paixao,. (2011). Laboratory animal models for brucellosis research. J Biomed Biotechnol 2011:518323
215. K.V.Singh, S.R.Nallapareddy, B.E.Murray. (2007). Importance of the ebp (endocarditis- and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection. J Infect Dis 195:1671–7
216. K.E.Sivick, H.L.Mobley. (2010). Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 78:568–85
217. K.E.Sivick, M.A.Schaller, S.N.Smith, H.L.Mobley. (2010). The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J Immunol 184:2065–75
218. A.Smithson, M.R.Sarrias, J.Barcelo,. (2005). Expression of interleukin-8 receptors (CXCR1 and CXCR2) in premenopausal women with recurrent urinary tract infections. Clin Diagn Lab Immunol 12:1358–63
219. J.A.Snyder, B.J.Haugen, E.L.Buckles,. (2004). Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect Immun 72:6373–81
220. J.Song, S.N.Abraham. (2008). TLR-mediated immune responses in the urinary tract. Curr Opin Microbiol 11:66–73
221. T.Springall, N.S.Sheerin, K.Abe,. (2001). Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nat Med 7:801–6
222. S.G.Stahlhut, C.Struve, K.A.Krogfelt, A.Reisner. (2012). Biofilm formation of Klebsiella pneumoniae on urethral catheters requires either type 1 or type 3 fimbriae. FEMS Immunol Med Microbiol 65:350–9
223. W.E.Stamm. (2006). Theodore E. Woodward Award: host–pathogen interactions in community-acquired urinary tract infections. Trans Am Clin Climatol Assoc 117:75–83; discussion 83–4
224. W.E.Stamm, T.M.Hooton. (1993). Management of urinary tract infections in adults. New Engl J Med 329:1328–34
225. W.E.Stamm, S.R.Norrby. (2001). Urinary tract infections: disease panorama and challenges. J Infect Dis 183:S1–4
226. A.Stapleton. (1999). Prevention of recurrent urinary-tract infections in women. Lancet 353:7–8
227. S.Subashchandrabose, T.H.Hazen, A.R.Brumbaugh,. (2014). Host-specific induction of Escherichia coli fitness genes during human urinary tract infection. Proc Natl Acad Sci USA 111:18327–32
228. F.Sunden, L.Hakansson, E.Ljunggren, B.Wullt. (2010). Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol 184:179–85
229. C.Svanborg, G.Bergsten, H.Fischer,. (2001). The ‘innate’ host response protects and damages the infected urinary tract. Ann Med 33:563–70
230. C.Svanborg Eden, D.Briles, L.Hagberg,. (1985). Genetic factors in host resistance to urinary tract infection. Infection 13:S171–6
231. M.Svensson, M.Yadav, B.Holmqvist,. (2011). Acute pyelonephritis and renal scarring are caused by dysfunctional innate immunity in mCxcr2 heterozygous mice. Kidney Int 80:1064–72
232. J.H.Tabibian, J.Gornbein, A.Heidari,. (2008). Uropathogens and host characteristics. J Clin Microbiol 46:3980–6
233. C.K.Tan, A.J.Carey, X.Cui,. (2012a). Genome-wide mapping of cystitis due to Streptococcus agalactiae and Escherichia coli in mice identifies a unique bladder transcriptome that signifies pathogen-specific antimicrobial defense against urinary tract infection. Infect Immun 80:3145–60
234. C.K.Tan, K.B.Ulett, M.Steele,. (2012b). Prognostic value of semi-quantitative bacteruria counts in the diagnosis of group B streptococcus urinary tract infection: a 4-year retrospective study in adult patients. BMC Infect Dis 12:273
235. D.Tena, A.Gonzalez-Praetorius, J.Bisquert. (2007). Urinary tract infection due to non-typhoidal Salmonella: report of 19 cases. J Infect 54:245–9
236. P.Tenke, B.Koves, T.E.Johansen. (2014). An update on prevention and treatment of catheter-associated urinary tract infections. Curr Opin Infect Dis 27:102–7
237. K.H.Thai, A.Thathireddy, M.H.Hsieh. (2010). Transurethral induction of mouse urinary tract infection. J Vis Exp 42:pii2070
238. M.Totsika, S.A.Beatson, S.Sarkar,. (2011). Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. PLoS One 6:e26578
239. M.Totsika, B.Heras, D.J.Wurpel, M.A.Schembri. (2009). Characterization of two homologous disulfide bond systems involved in virulence factor biogenesis in uropathogenic Escherichia coli CFT073. J Bacteriol 191:3901–8
240. M.Totsika, M.Kostakioti, T.J.Hannan,. (2013). A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis 208:921–8
241. A.Tratselas, M.Simitsopoulou, A.Giannakopoulou,. (2014). Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 58:7102–11
242. B.W.Trautner. (2010). Management of catheter-associated urinary tract infection. Curr Opin Infect Dis 23:76–82
243. B.W.Trautner, R.A.Hull, R.O.Darouiche. (2005). Prevention of catheter-associated urinary tract infection. Curr Opin Infect Dis 18:37–41
244. J.J.Tree, G.C.Ulett, C.L.Ong,. (2008). Trade-off between iron uptake and protection against oxidative stress: deletion of cueO promotes uropathogenic Escherichia coli virulence in a mouse model of urinary tract infection. J Bacteriol 190:6909–12
245. M.Tsuji, M.Takema, H.Miwa,. (2003). In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob Agents Chemother 47:2507–12
246. K.B.Ulett, W.H.BenjaminJr, F.Zhuo,. (2009). Diversity of group B streptococcus serotypes causing urinary tract infection in adults. J Clin Microbiol 47:2055–60
247. K.B.Ulett, J.H.Shuemaker, W.H.BenjaminJr,. (2012). Group B streptococcus cystitis presenting in a diabetic patient with a massive abdominopelvic abscess: a case report. J Med Case Rep 6:237–40
248. G.C.Ulett, M.Totsika, K.Schaale,. (2013). Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection. Curr Opin Microbiol 16:100–7
249. G.C.Ulett, J.Valle, C.Beloin,. (2007). Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract. Infect Immun 75:3233–44
250. G.C.Ulett, R.I.Webb, K.B.Ulett,. (2010). Group B Streptococcus (GBS) urinary tract infection involves binding of GBS to bladder uroepithelium and potent but GBS-specific induction of interleukin 1alpha. J Infect Dis 201:866–70
251. A.Umpierrez, P.Scavone, D.Romanin,. (2013). Innate immune responses to Proteus mirabilis flagellin in the urinary tract. Microbes Infect 15:688–96
252. D.Van Duin. (2012). Diagnostic challenges and opportunities in older adults with infectious diseases. Clin Infect Dis 54:973–8
253. H.C.Vebo, M.Solheim, L.Snipen,. (2010). Comparative genomic analysis of pathogenic and probiotic Enterococcus faecalis isolates, and their transcriptional responses to growth in human urine. PLoS One 5:e12489
254. S.Vimont, A.Boyd, A.Bleibtreu,. (2012). The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 7:e46547
255. E.Vivaldi. (1968). Effect of chronic administration of analgesics on resistance to experimental infection of the urinary tract in rats. Nephron 5:202–9
256. F.M.Wagenlehner, K.G.Naber. (2004). Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections. Int J Antimicrob Agents 23:S24–9
257. C.Wang, J.W.Symington, E.Ma,. (2013). Estrogenic modulation of uropathogenic Escherichia coli infection pathogenesis in a murine menopause model. Infect Immun 81:733–9
258. C.Wang, X.Yuan, E.Ma,. (2014). NOD2 is dispensable for ATG16L1 deficiency-mediated resistance to urinary tract infection. Autophagy 10:331–8
259. J.W.Warren, J.H.Tenney, J.M.Hoopes,. (1982). A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 146:719–23
260. R.E.Watts, C.K.Tan, G.C.Ulett,. (2012a). Escherichia coli 83972 expressing a P fimbriae oligosaccharide receptor mimic impairs adhesion of uropathogenic E. coli. J Infect Dis 206:1242–9
261. R.E.Watts, M.Totsika, V.L.Challinor,. (2012b). Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli. Infect Immun 80:333–44
262. A.Wieser, E.Romann, G.Magistro,. (2010). A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 78:3432–42
263. D.Wobser, L.Ali, E.Grohmann,. (2014). A novel role for D-alanylation of lipoteichoic acid of Enterococcus faecalis in urinary tract infection. PLoS One 9: e107827
264. X.R.Wu, T.T.Sun, J.J.Medina. (1996). In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci USA 93:9630–5
265. B.Wullt. (2003). The role of P fimbriae for Escherichia coli establishment and mucosal inflammation in the human urinary tract. Int J Antimicrob Agents 21:605–21
266. B.Wullt, G.Bergsten, H.Connell,. (2001). P-fimbriae trigger mucosal responses to Escherichia coli in the human urinary tract. Cell Microbiol 3:255–64
267. B.Wullt, G.Bergsten, H.Fischer,. (2003). The host response to urinary tract infection. Infect Dis Clin North Am 17:279–301
268. B.Wullt, G.Bergsten, M.Samuelsson, C.Svanborg. (2002). The role of P fimbriae for Escherichia coli establishment and mucosal inflammation in the human urinary tract. Int J Antimicrob Agents 19:522–38
269. B.Wullt, H.Connell, P.Rollano,. (1998). Urodynamic factors influence the duration of Escherichia coli bacteriuria in deliberately colonized cases. J Urol 159:2057–62
270. M.Yadav, J.Zhang, H.Fischer,. (2010). Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence. PLoS Pathog 6:e1001120
271. X.Yin, T.Hou, Y.Liu,. (2010). Association of toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 5:e14223
272. X.F.You, C.R.Li, X.Y.Yang,. (2009). In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic. Antimicrob Agents Chemother 53:4525–8
273. Z.Zhang, L.Jin, G.Champion,. (2001). Shigella infection in a SCID mouse–human intestinal xenograft model: role for neutrophils in containing bacterial dissemination in human intestine. Infect Immun 69:3240–7
274. D.Zhang, G.Zhang, M.S.Hayden,. (2004). A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303:1522–6